本文選題：急性肺損傷 + 全氟異丁烯�。� 參考：《中國職業(yè)醫(yī)學(xué)》2014年03期

【摘要】：目的探討血管緊張素Ⅱ1型受體(AT1-R)阻斷劑氯沙坦鉀在全氟異丁烯(PFIB)急性肺損傷(ALI)中的防治作用。方法無特定病原體級(jí)成年雄性Wistar大鼠68只,分為17個(gè)組,每組4只。時(shí)間-效應(yīng)關(guān)系研究中,設(shè)PFIB染毒前1.0、0.5 h與染毒后0.5、1.0、2.0、4.0、8.0 h氯沙坦鉀干預(yù)組,并設(shè)氯沙坦鉀對(duì)照組,上述8組固定氯沙坦鉀給藥劑量為10.00 mg/kg體質(zhì)量;劑量-效應(yīng)關(guān)系研究中,設(shè)氯沙坦鉀給藥劑量分別為1.25、2.50、5.00、10.00和15.00 mg/kg體質(zhì)量的干預(yù)組,固定給藥時(shí)間為染毒前1.0 h。上述2種關(guān)系研究中,均設(shè)空白對(duì)照組和PFIB染毒對(duì)照組。采用大鼠頭部暴露動(dòng)態(tài)吸入染毒法建立PFIB吸入性ALI模型,各干預(yù)組和PFIB染毒對(duì)照組染毒劑量均為145 mg/m3×8 min,空白對(duì)照組和氯沙坦鉀對(duì)照組均行過濾空氣暴露8 min。染毒后24 h處死動(dòng)物,分別收集右肺組織及左肺支氣管肺泡灌洗液(BALF),測定肺濕/干質(zhì)量比、肺含水量、濕肺體比、干肺體比4個(gè)肺系數(shù)和BALF總蛋白水平。結(jié)果時(shí)間-效應(yīng)關(guān)系研究中,PFIB染毒對(duì)照組肺濕/干質(zhì)量比、肺含水量、濕肺體比3個(gè)肺系數(shù)以及BALF總蛋白水平均分別高于空白對(duì)照組、氯沙坦鉀對(duì)照組(P0.05);7個(gè)時(shí)間氯沙坦鉀干預(yù)組的4個(gè)肺系數(shù)指標(biāo)以及BALF總蛋白水平分別與PFIB染毒對(duì)照組比較,差異均無統(tǒng)計(jì)學(xué)意義(P0.05)。劑量-效應(yīng)關(guān)系研究中,PFIB染毒對(duì)照組的4個(gè)肺系數(shù)和BALF總蛋白水平均分別高于空白對(duì)照組(P0.05);5個(gè)劑量氯沙坦鉀干預(yù)組的4個(gè)肺系數(shù)以及BALF總蛋白水平分別與PFIB染毒對(duì)照組比較,差異均無統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論 AT1-R阻斷劑氯沙坦鉀對(duì)PFIB吸入性ALI無明顯影響,提示血管緊張素Ⅱ在PFIB中毒性肺損傷中作用有限。
[Abstract]:Objective to investigate the protective effect of losartan potassium on acute lung injury of perfluoroisobutylene perfluorobutylene perfluorobutene (PFIBF). Methods 68 adult male Wistar rats without specific pathogens were divided into 17 groups with 4 rats in each group. In the study of time-effect relationship, the dosage of losartan potassium was 10.00 mg/kg body mass in the 8 groups, the dose of Losartan potassium was 10.00 mg/kg body mass in the control group, and the dosage of losartan potassium was 10.00 mg/kg body weight in the study of dose-effect relationship, the dosage of losartan potassium was 10.00 mg/kg body mass in the study of dose-effect relationship, and the dosage of losartan potassium was 10.00 mg/kg body weight in the study of dose-effect relationship. The dosage of losartan potassium was 1.25U 2.50m 5.0010.00 and 15.00 mg/kg body weight, respectively, and the fixed time was 1.0 h before exposure to Losartan. In the above two relation studies, there were blank control group and PFIB exposure control group. PFIB inhalation ALI model was established by dynamic inhalation of rat head exposure. The dose of each intervention group and PFIB control group was 145 mg/m3 脳 8 min, and the blank control group and losartan potassium control group were exposed to filtered air for 8 min. The right lung tissue and left lung bronchoalveolar lavage fluid (BALFN) were collected 24 hours after exposure. Lung wet / dry mass ratio, lung water content, wet lung body ratio, dry lung body ratio and BALF total protein level were measured. Results the lung wet / dry weight ratio, lung water content, three lung coefficients of wet lung to body ratio and the total protein level of BALF in the control group were higher than those in the blank control group, respectively. There was no significant difference in lung coefficient index and BALF total protein level between Losartan potassium control group and PFIB exposed control group at 7 hours after treatment with Losartan potassium, and there was no significant difference between Losartan potassium control group and PFIB exposed control group (P 0.05). In the dose-response study, the four lung coefficients and BALF total protein levels in the PFIB-exposed control group were higher than those in the blank control group, respectively, and the four lung coefficients and the BALF total protein levels in the five doses of losartan potassium intervention group were compared with those in the PFIB exposed control group, respectively. The difference was not statistically significant (P 0.05). Conclusion Losartan potassium, a AT1-R blocker, has no significant effect on PFIB inhaled ALI, suggesting that angiotensin 鈪，

本文編號(hào)：1777842